Citadel Advisors
ANVS icon

Citadel Advisors’s Annovis Bio ANVS Stock Holding History

Citadel Advisors’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Buy
+243,682
New +$474K ﹤0.01% 10102
2025
Q4 		– Sell
-174,345
Closed -$524K – 12582
2025
Q3 		$361K Buy
174,345
+145,019
+495% +$362K ﹤0.01% 9928
2025
Q2 		$63.6K Buy
+29,326
New +$57.9K ﹤0.01% 11647
2025
Q1 		– Sell
-215,207
Closed -$659K – 14413
2024
Q4 		$1.08M Buy
215,207
+112,515
+110% +$814K ﹤0.01% 6848
2024
Q3 		$828K Buy
+102,692
New +$962K ﹤0.01% 7241
2024
Q2 		– Sell
-1
Closed -$8 – 14179
2024
Q1 		$12 Buy
+1
New +$11 ﹤0.01% 14460
2022
Q1 		– Sell
-59,147
Closed -$1.04M – 13504
2021
Q4 		$1.04M Buy
59,147
+21,925
+59% +$565K ﹤0.01% 7849
2021
Q3 		$1.18M Buy
+37,222
New +$2.14M ﹤0.01% 7716
2021
Q2 		– Sell
-8,963
Closed -$250K – 13608
2021
Q1 		$250K Buy
+8,963
New +$192K ﹤0.01% 11228

Other funds holding ANVS

EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors's ANVS Position: Q2 2026 in Review

Citadel Advisors opened a new position in Annovis Bio (ANVS) in Q2 2026: 243,682 shares worth $453K. The stake represents ﹤0.01% of the portfolio and ranks #10102 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ANVS as recently as Q3 2025.

Citadel Advisors first reported a position in ANVS in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.18M in Q3 2021. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

  • Citadel Advisors held 243,682 shares of Annovis Bio worth $453K as of Q2 2026.
  • Annovis Bio was a new Citadel Advisors position in Q2 2026.
  • Annovis Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10102 holding.
  • Citadel Advisors first reported a position in Annovis Bio in Q1 2021 and has held it in 9 quarters since.
  • Citadel Advisors's Annovis Bio position peaked at $1.18M in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.